Glycemic variability and indices of glycemic control among pregnant women with type 1 diabetes (T1D) based on the use of continuous glucose monitoring share technology

J Matern Fetal Neonatal Med. 2022 Dec;35(25):8968-8974. doi: 10.1080/14767058.2021.2008895. Epub 2021 Dec 7.

Abstract

Background: Pregnancies complicated by type 1 diabetes (T1D) experience high levels of glycemic variability, which may be associated with adverse maternal and neonatal outcomes. Therefore, strategies that help pregnant women with T1D manage their glycemic control are of great interest.

Methods: We examined associations with or without remote monitoring of Continuous Glucose Monitor (CGM) data by friends and family with indices of glycemic control and glycemic variability during pregnancies complicated by T1D in a pilot non-randomized trial (n = 28). During preconception or the first trimester, participants were placed in one of two groups based on device compatibility: (1) CGM Alone (n = 13): women without iPhone, iPad or iPod Touch; or (2) CGM Share (n = 15): women with iPhone, iPad, or iPod Touch and followers with devices compatible for data viewing. Linear mixed models were used to compare indices of glycemic control and glycemic variability over time between groups.

Results: Participants using CGM Share had lower estimated HbA1c levels over time (p = .028), glucose management index (p = .041), and fewer glucose excursions >200 mg/dL in each trimester (p = .022) compared to those using CGM Alone. Participants using CGM Alone had higher high blood glucose index (p = .020), mean area under the curve (p = .026), and standard deviation (p = .046) compared to those using CGM Share. Other measures of glycemic variability did not differ between groups.

Conclusion: In this non-randomized pilot study, use of CGM Share was associated with improvements in several indices of glycemic control and glycemic variability.

Keywords: Type 1 diabetes; continuous glucose monitoring; glucose monitoring; glycemic variability; pregnancy.

MeSH terms

  • Blood Glucose Self-Monitoring
  • Blood Glucose*
  • Diabetes Mellitus, Type 1* / drug therapy
  • Female
  • Glycated Hemoglobin / analysis
  • Glycemic Control
  • Humans
  • Hypoglycemic Agents
  • Infant, Newborn
  • Non-Randomized Controlled Trials as Topic
  • Pilot Projects
  • Pregnancy
  • Pregnant People
  • Technology

Substances

  • Blood Glucose
  • Glycated Hemoglobin A
  • Hypoglycemic Agents